Dr. Kibar is an entrepreneur and an inventor, with numerous successful start-ups under his belt. He was the Scientific Founder of Genoptix (an oncology diagnostics company), which went public in 2007 (NASDAQ: GXDX) and was later acquired by Novartis in 2011. Dr. Kibar was also a Co-Founder of E-Tenna, whose assets relating to wireless antennas were acquired by Titan and assets relating to thermal management of microprocessors by Intel. He was a Vice President at Pequot Capital's venture capital and private equity team.

Dr. Kibar received his MS and PhD, specializing in Biophotonics and Optoelectronics, from University of California, San Diego, a BS in Electrical Engineering from Caltech and a BA in Mathematical Economics from Pomona College.

Troy Cox, former CEO of Foundation Medicine, is striving to make a difference in patients’ lives by serving on the boards of innovative growth companies in the Biotech, Genetics, Diagnostic, and Digital Health industries. As President and Chief Executive Officer, Mr. Cox led Foundation Medicine (NASDAQ: FMI) through the acquisition by Roche for $5.3 billion in 2018. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth to over $12 billion while accountable to help steer the Roche Genentech R&D portfolio. Before Genentech, Mr. Cox held executive and senior roles of increasingly broad accountabilities including President UCB BioPharmaceuticals, Senior Vice President Sanofi-Aventis and diverse foundational roles at Schering-Plough. Mr. Cox received his MBA at the University of Missouri and BBA in Finance from the University of Kentucky. He is Chairman of Sophia Genetics (Series F), Vice Chairman of LetsGetChecked (Series C), Board Director at Zymeworks (NYSE: ZYME) and CM Life Sciences II as well as non-profits Massachusetts BioTechnology Council (MassBio) and Dream Foundation.

Susannah Gray brings more than 30 years of biopharmaceutical experience specifically in corporate finance and capital markets roles, most recently serving as EVP, Finance & Strategy of Royalty Pharma Management, LLC. Ms. Gray spent 14 years as Executive Vice President and Chief Financial Officer of Royalty Pharma before retiring in 2019 just ahead of the Company’s initial public offering. At Royalty Pharma, Ms. Gray led the Company’s efforts to maximize its financial capabilities. In her career at Royalty Pharma, she increased the debt facilities from approximately $200 million to $7 billion, and was responsible for over $20 billion in total financing. She also raised $2.0 billion equity capital for the Company.

Prior to joining Royalty Pharma, Ms. Gray had a 14-year career in investment banking. In her most recent role, she was a Managing Director and the Senior Analyst covering the healthcare sector for CIBC World Market’s high yield group from 2002 to 2004. She worked in a similar capacity at Merrill Lynch prior to joining CIBC World Markets. Ms. Gray joined Merrill Lynch in April 1999 after nine years at Chase Securities (a predecessor of JP Morgan), working in various capacities within the high yield and the structured finance groups. Ms. Gray received a BA with honors from Wesleyan University and holds an MBA degree from Columbia University. Ms. Gray currently serves on the board of directors of Susan G. Komen and is on the board of trustees at Wesleyan University.

Mr. Samikoglu is a public and private investor, entrepreneur and a former investment banker. Prior to Biosplice, he was the Co-Founder, Portfolio Manager and a Partner of Greywolf Capital Management LP, a New York-based investment fund managing capital in different strategies. Prior to forming Greywolf, he was the Director of Research and a Portfolio Manager of Goldman Sachs’ Special Situations Investing Group. Mr. Samikoglu began his career at Goldman, Sachs & Co. where he spent nine years, both as a proprietary investor and as an investment banker.

Mr. Samikoglu received his MBA from Harvard Business School and his BA in Economics from Hamilton College.

Dr Finian Tan is a venture capitalist, entrepreneur, and the founder and current chairman of Vickers Venture Partners, an international venture capital firm with a presence in Singapore, Shanghai, New York, Hong Kong, Silicon Valley, and San Francisco. Before he started Vickers, Dr. Tan was Managing Director and head of the Credit Suisse First Boston’s (“CSFB”) group of banks in Singapore and Malaysia, a role he took on after leaving his position as the Founding Partner and Managing Director of Silicon Valley venture capital firm Draper Fisher Jurvetson ePlanet for Asia, where he made an early and probably his most famous investment in Chinese tech giant Baidu. Prior to this, in 1997, Dr. Tan served as Deputy Secretary of the Ministry of Trade and Industry for the Singapore Government.

Dr. Tan received his Doctor of Philosophy from Cambridge University on the Shell/Cambridge Scholarship. He received his B.Sc. Degree in Engineering from the University of Glasgow, where he also won all the academic awards available for the examinations, including an award for being the top student for his course, as well as the most distinguished graduate award.